Condition: Solid Tumor · NSCLC · Sponsor: Ono Pharmaceutical Co., Ltd.
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
This description comes directly from the study's public registry record.
North America Clinical Trial Support Desk · +18665877745(Toll-Free) · clinical_trial@ono-pharma.com
International Clinical Trial Support Desk · +17162141777(Standard) · clinical_trial@ono-pharma.com
Always discuss trial participation with your own doctor first.
| Nagoya University Hospital | Nagoya, Aichi-ken, Japan | Recruiting |
| National Cancer Center Hospital East | Kashiwa, Chiba, Japan | Recruiting |
| Kurume University Hospital | Kurume, Fukuoka, Japan | Recruiting |
| Hyogo Medical University Hospital | Nishinomiya, Hyōgo, Japan | Recruiting |
| Kitasato University Hospital | Sagamihara, Kanagawa, Japan | Recruiting |
| Kanagawa Cancer Center | Yokohama, Kanagawa, Japan | Recruiting |
| Kochi Medical School Hospital | Nankoku, Kochi, Japan | Recruiting |
| Kyoto University Hospital | Kyoto, Kyoto, Japan | Recruiting |
| Kansai Medical University Hospital | Hirakata, Osaka, Japan | Recruiting |
| Osaka International Cancer Institute | Osaka, Osaka, Japan | Recruiting |
| Kindai University Hospital | Sakai, Osaka, Japan | Recruiting |
| Saitama Medical University International Medical Center | Hidaka, Saitama, Japan | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06816108